I am an Immunologist, who has worked in several immunology fields, from veterinary to human immunology and from basic to translational research. I did my PhD at Centre de Recerca en Sanitat Animal (CReSA), working on the development of novel vaccine strategies against African Swine Fever Virus (ASFV). Results obtained demonstrated the potential of DNA vaccines to induce protective immunity against this virus, and highlighted the importance of cellular immunity to fight the disease. During my PhD I had also the opportunity to interact with other groups within CReSA and other institutions such as CISA-INIA (Spain), the Pirbright Institute (UK), and AFSSA (France). From these collaborations I became co-author in publications about Foot-and-mouth Disease Virus, Porcine Circovirus 2, Classical Swine Fever Virus and Influenza Virus. Additionally, I did the PhD courses in the Program of Animal Health, expanding my knowledge in the veterinary field. After my PhD, I enjoyed a 10-year postdoctoral position at the PRBB biomedicine research hub, in the Infection Biology group headed by Dr. Andreas Meyerhans (Universitat Pompeu Fabra-PRBB, Barcelona). My work there focused on the study of interactions between the immune system and pathogens causing persistent infections. The main aims of my research were (i) to understand the factors that regulate the decision between an acute versus a persistent infection course, and (ii) to define the factors that control the dynamic balance of virus expansion and immune control in persistent infections. To address these issues, I used the Lymphocytic Choriomeningitis Virus (LCMV)-infection mouse model system, and performed a systems biology approach in collaboration with the bioinformatician Dr. Anna Esteve-Codina from CNAG-GRC. The main publications derived from this project (Argilaguet et al. 2018 Genome Research; Domenjo-Vila et al. 2023 Cell Reports) are relevant for the understanding of critical steps in the host adaptation process to a viral chronic infection. In addition to the work with animal models, I established collaborations with clinicians and international mathematical modelers to study the immune factors that contribute to the efficacy of novel treatments for HIV infection and cancer. From the several publications that resulted from these collaborations, I consider of special interest the characterization of the effect of immune checkpoint inhibitors on different immune cell subsets from HIV-infected patients (Peligero et al. 2015 Plos Path; Zheltkova et al. 2019 Plos Comp. Biol.) and their feasibility to treat tumors in IHV-infected patients (Gonzalez-Cao et al. 2020 JAMA Oncol.). While addressing all these issues I participated in six competitive research grants, and acquired experience in grant application, project management, supervision of 4 PhD students, and writing of scientific articles and projects. In this period, I also took advantage of the PRBB facilities, which allowed me to get familiar with state-of-the-art technologies such as advanced flow cytometry and bulk and single-cell RNA-sequencing, and I established long-term collaborations with experts on these areas. During these ten years, I progressively developed the necessary skills to become an independent researcher. Since 2020 I work at IRTA-CReSA leading immunological studies related to several pathogens of interest for Animal Health, with a special focus on ASF immunology. Indeed, I have become the head of the ASFV group, complement the previous expertise in ASF vaccinology with my knowledge in basic immunology and -omic technologies. Also, I am responsible of research contracts with international companies to develop effective vaccines against ASFV, including studies based on good laboratory practices (GLP). In addition, I also led a research contract with a private company as principal investigator, collaborated with other groups in other research projects that resulted in several publications. In parallel with my scientific responsibilities as a researcher, I am also leading the IRTA-CReSA Flow Cytometry Service, which currently consist in a sorter BD Discovery S8 placed in CReSA BSL-3 facilities. User of this service, singular in its capacity to sort cells from BSL-3 infectious samples, are both internal research groups form IRTA, as well as external researchers from other institutions or pharmaceutical companies.